It's a great catch for Owkin.
The artificial intelligence unicorn applied to health debauchery at Sanofi.
After six years in the house, Alban de La Sablière became director of business development for the young Franco-American company.
For this former investment banker (Morgan Stanley), who made his first deals in pharma - including Sanofi-Aventis - in the early 2000s, it was a fairly
"irresistible"
call .
"The convergence between artificial intelligence, the wealth of available data and advances in biology will revolutionize the sector,
" he says.
It is rare to have a company that combines such a level in these areas.”
On the lookout for opportunities
The 40-year-old, who led Sanofi's international partnerships, is not arriving in uncharted territory.
It was his team that piloted the agreement between Owkin and Sanofi, sealed last year, around R&D programs in four forms of cancer.
The French laboratory, which injected 180 million euros, became a shareholder…
This article is for subscribers only.
You have 63% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for €0.99 for the first month
I ENJOY IT
Already subscribed?
Login
/cloudfront-eu-central-1.images.arcpublishing.com/prisa/CY3MBVCW4BE4ZPFNI4WI4AQ6IE.jpg)
